Loading
A phase 3 trial of Tunlametinib run by Shanghai Kechow Pharma, Inc. in melanoma, now recruiting.
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma is a phase 3 interventional study registered as NCT06008106 by Shanghai Kechow Pharma, Inc., with 165 participants planned, started 2023-11-02. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
Shares Shanghai Kechow Pharma, Tunlametinib, Small-molecule kinase inhibitors.
Shares Acral melanoma, Mucosal melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Acral melanoma, Mucosal melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Acral melanoma, Mucosal melanoma.
Shares Acral melanoma, Mucosal melanoma.
Shares Acral melanoma, Mucosal melanoma.
Shares Acral melanoma, Mucosal melanoma.
Shares Acral melanoma, Mucosal melanoma, Melanoma.